Cantor Fitzgerald Begins Coverage on Zevra Therapeutics (NASDAQ:ZVRA)

Analysts at Cantor Fitzgerald initiated coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research note issued on Wednesday. The firm set an “overweight” rating and a $25.00 price target on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 193.08% from the company’s current price.

Several other brokerages have also issued reports on ZVRA. Roth Mkm boosted their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Guggenheim initiated coverage on Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 target price for the company. Maxim Group raised their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Stock Up 3.5 %

Shares of ZVRA stock opened at $8.53 on Wednesday. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm has a market cap of $455.30 million, a PE ratio of -4.33 and a beta of 2.01. The stock has a 50 day moving average of $8.78 and a 200-day moving average of $7.58.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter in the previous year, the company earned ($0.40) earnings per share. On average, equities analysts predict that Zevra Therapeutics will post -1.96 EPS for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Several large investors have recently made changes to their positions in ZVRA. Vestal Point Capital LP bought a new stake in Zevra Therapeutics during the third quarter worth about $3,644,000. Sanctuary Advisors LLC bought a new stake in Zevra Therapeutics during the 2nd quarter worth approximately $474,000. Geode Capital Management LLC grew its position in Zevra Therapeutics by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after acquiring an additional 129,600 shares during the last quarter. Propel Bio Management LLC bought a new position in Zevra Therapeutics in the 3rd quarter valued at $1,248,000. Finally, Simplify Asset Management Inc. acquired a new position in Zevra Therapeutics in the third quarter worth $833,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.